The decision of the Indian Supreme Court to deny
Novartis’s application for patent protection for an improved
version of its patented Glivec drug – the
culmination of a seven-year battle - has certainly made the
headlines. There are a number of reasons for this. First, Glivec is
a well-known drug – described by some as a ‘wonder
drug’ – that’s used to combat cancer,
including leukaemia and gastro-intestinal cancer.
Second, pharmaceutical patents are inherently controversial
because they’re emotive – pharmaceutical companies
argue that they deserve as much protection as they can get because
so much research and development goes into drugs, whereas
civil society often argues that patents allow the drugs companies
to charge a premium, thereby placing life-saving drugs beyond the
reach of much of the world’s population . And third, the
Glivec case dealt with the issue of
‘evergreening’, which is the practice of
patenting modifications or improvements to a patented